Clinical trials
catalyst calendar across sponsors →Studies where PRME is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 observational
Held by 12 tracked-famous managers (Balyasny Asset Management L.P., CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, +7 more) · FINRA short interest 12.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )NCT06559176Safety of administration of PM359, as quantified by frequency of adverse events (AEs) after drug product infusionOpen-label · Treatment | Phase 1/2 | Enrolling by invitation | Biological: PM359 | Chronic Granulomatous Disease, Granulomatous Disease, Chronic | 12 | Jan 2030 | ≤ 1,261 d | 2026-04-06 |
| A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)NCT07748403Safety and tolerability of PM577a. Quantified by frequency and severity of treatment emergent adverse events (TEAEs).Open-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: PM577a | Wilson Disease, Wilson's Disease, Wilsons Disease | 42 | Nov 2028 | ≤ 834 d | 2026-08-11 |
| Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical TrialNCT07226622observationalGene Editing Interest & Attitudes Survey | — | Active, not recruiting | — | Wilson Disease | 30 | Dec 2027 | ≤ 499 d | 2026-05-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19